PCVX · Company research

Vaxcyte, Inc.

3 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsPCVXVaxcyteQ4 2026

Vaxcyte expects to report results from its Phase 3 study of VAX-31 for Invasive pneumococcal disease/pneumonia prevention, adults in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

OPUS-1 Phase 3 pivotal topline for VAX-31 in adults · Clinical trial results (readout / topline data)

Drug

VAX-31

For

Invasive pneumococcal disease/pneumonia prevention, adults

Stage

Phase 3 · the last stage before a drug can be approved

When

Q4 2026 · the company gave a window, not a day

Source note

Q2 2026 update (Aug 5, 2026): topline safety, tolerability and immunogenicity data from OPUS-1 (4,049 participants) expected in fourth quarter of 2026.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
PCVX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsPCVXVaxcyteH1 2027

Vaxcyte expects to report results from its Phase 3 study of VAX-31 for Invasive pneumococcal disease/pneumonia prevention, adults in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

OPUS-2 and OPUS-3 Phase 3 data for VAX-31 in adults · Clinical trial results (readout / topline data)

Drug

VAX-31

For

Invasive pneumococcal disease/pneumonia prevention, adults

Stage

Phase 3 · the last stage before a drug can be approved

When

H1 2027 · the company gave a window, not a day

Source note

Q2 2026 update: OPUS-2 (flu co-administration) and OPUS-3 (previously vaccinated adults) data expected in first half of 2027; BLA submission planned thereafter.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
PCVX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsPCVXVaxcyteH2 2027

Vaxcyte expects to report results from its Phase 1 study of VAX-A1 for Group A Strep vaccine in the second half of 2027 (no exact date yet). Phase 1 is an early safety study in a small group of people.

More details

Entry

VAX-A1 Phase 1 topline in adults · Clinical trial results (readout / topline data)

Drug

VAX-A1

For

Group A Strep vaccine

Stage

Phase 1 · an early safety study in a small group of people

When

H2 2027 · the company gave a window, not a day

Source note

Q2 2026 update: topline Phase 1 data in adults expected in the second half of 2027.

Checked

Checked by a person when it was added

Verify it

Source: biospace.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
PCVX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

MilestonePCVXVaxcyteJun 2, 2026

First participant dosed in Phase 1 study of VAX-A1 for Group A Strep, on Jun 2, 2026. A company milestone for Vaxcyte (VAX-A1 for Group A Streptococcus disease prevention): a step in the program rather than a decision or a data readout.

More details

Entry

First participant dosed in Phase 1 study of VAX-A1 for Group A Strep · Company milestone

Drug

VAX-A1

For

Group A Streptococcus disease prevention

Stage

Phase 1 · an early safety study in a small group of people

When

Jun 2, 2026

Source note

Vaxcyte began its first-in-human, placebo-controlled dose-escalation study of VAX-A1 in healthy adults aged 18-40, the first clinical asset from its non-pneumococcal pipeline. Topline data are expected in the second half of 2027.

Checked

Checked by a person when it was added

Verify it

Source: investors.vaxcyte.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
PCVX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestonePCVXVaxcyteMar 23, 2026

OPUS-1 and OPUS-2 Phase 3 enrollment complete; OPUS-1 topline due 4Q26, on Mar 23, 2026. A company milestone for Vaxcyte (VAX-31 for Invasive pneumococcal disease and pneumonia (adults)): a step in the program rather than a decision or a data readout.

More details

Entry

OPUS-1 and OPUS-2 Phase 3 enrollment complete; OPUS-1 topline due 4Q26 · Company milestone

Drug

VAX-31

For

Invasive pneumococcal disease and pneumonia (adults)

Stage

Phase 3 · the last stage before a drug can be approved

When

Mar 23, 2026

Source note

Vaxcyte finished enrolling roughly 4,000 participants in the pivotal non-inferiority OPUS-1 trial and about 1,300 in OPUS-2, locking in the timing of the key VAX-31 adult readout. OPUS-1 topline immunogenicity data were guided to Q4 2026.

Checked

Checked by a person when it was added

Verify it

Source: investors.vaxcyte.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
PCVX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestonePCVXVaxcyteMar 18, 2026

VAX-31 adult Phase 1/2 data published in Lancet Infectious Diseases, on Mar 18, 2026. A company milestone for Vaxcyte (VAX-31 for Invasive pneumococcal disease and pneumonia (adults 50+)): a step in the program rather than a decision or a data readout.

More details

Entry

VAX-31 adult Phase 1/2 data published in Lancet Infectious Diseases · Company milestone

Drug

VAX-31

For

Invasive pneumococcal disease and pneumonia (adults 50+)

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

Mar 18, 2026

Source note

The Lancet Infectious Diseases published the positive adult Phase 1/2 study of VAX-31 versus Prevnar 20, showing comparable tolerability and robust OPA and IgG responses across all 31 serotypes. The high dose carried into the OPUS Phase 3 program.

Checked

Checked by a person when it was added

Verify it

Source: investors.vaxcyte.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
PCVX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to PCVX.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.